Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib Master Protocol Continuation Study
2021-006010-37Phase 4Active
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crizotinib in Nonhematologic neoplasms and cancer, sponsored by Pfizer. Primary endpoint: Adverse events leading to permanent discontinuation of crizotinib. Started Mar 2022; status: active.
02
Drugs
crizotinib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2021-006010-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006010-37.